Recent Advances in Biomaterials‐Based Therapies for Alleviation and Regeneration of Traumatic Brain Injury

Hu, Hongbo; Chen, Xiping; Zhao, Kefei; Zheng, Weiwei; Gao, Changyou

doi:10.1002/mabi.202200577

Cited by 11 publications

(3 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, tissue engineering strategies with biomaterials as the core provide a new direction for the treatment of spinal cord injury. Biomaterials can fill the cavities of the spinal cord injury site, load therapeutic drugs, induce differentiation of endogenous/exogenous neural stem cells into functional cells to bridge the severed spinal cord, improve the local microenvironment of the injury site, and promote functional recovery ( Fuhrmann et al, 2017 ; Yang et al, 2020 ; Luo et al, 2022 ; Hu et al, 2023 ). Biomaterials combined with cytokines or stem cells can reduce the size of the injury area, diminish scar formation, promote neural regeneration, and restore motor function ( Shrestha et al, 2014 ; Zhao et al, 2017a ; Fuhrmann et al, 2017 ).…”

Section: Discussionmentioning

confidence: 99%

Bibliometric analysis of stem cells for spinal cord injury: current status and emerging frontiers

Shang,

Wanyan,

Wang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: This study aimed to conduct a bibliometric analysis of the literature on stem cell therapy for spinal cord injury to visualize the research status, identify hotspots, and explore the development trends in this field.Methods: We searched the Web of Science Core Collection database using relevant keywords (“stem cells” and “spinal cord injury”) and retrieved the published literature between 2000 and 2022. Data such as journal title, author information, institutional affiliation, country, and keywords were extracted. Afterwards, we performed bibliometric analysis of the retrieved data using Bibliometrix, VOSviewer, and CiteSpace.Results: A total of 5375 articles related to stem cell therapy for spinal cord injury were retrieved, and both the annual publication volume and the cumulative publication volume showed an upward trend. neural regeneration research was the journal with the most publications and the fastest cumulative publication growth (162 articles), Okano Hideyuki was the author with the highest number of publications and citations (114 articles), Sun Yat-sen University was the institution with the highest number of publications (420 articles), and China was the country with the highest number of publications (5357 articles). However, different authors, institutions, and countries need to enhance their cooperation in order to promote the generation of significant academic achievements. Current research in this field has focused on stem cell transplantation, neural regeneration, motor function recovery, exosomes, and tissue engineering. Meanwhile, future research directions are primarily concerned with the molecular mechanisms, safety, clinical trials, exosomes, scaffolds, hydrogels, and inflammatory responses of stem cell therapy for spinal cord injuries.Conclusion: In summary, this study provided a comprehensive analysis of the current research status and frontiers of stem cell therapy for spinal cord injury. The findings provide a foundation for future research and clinical translation efforts of stem cell therapy in this field.

show abstract

Section: Discussionmentioning

confidence: 99%

Bibliometric analysis of stem cells for spinal cord injury: current status and emerging frontiers

Shang,

Wanyan,

Wang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…To address these limitations, several key solutions can be implemented [219][220][221]. These include the development of minimally invasive surgical techniques to reduce the invasiveness of and the complications associated with implanting the scaffolds.…”

Section: Complications Limitations and Recommendationsmentioning

confidence: 99%

Biomaterials in Traumatic Brain Injury: Perspectives and Challenges

Aqel,

Al-Thani,

Haider

et al. 2023

Biology

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a leading cause of mortality and long-term impairment globally. TBI has a dynamic pathology, encompassing a variety of metabolic and molecular events that occur in two phases: primary and secondary. A forceful external blow to the brain initiates the primary phase, followed by a secondary phase that involves the release of calcium ions (Ca2+) and the initiation of a cascade of inflammatory processes, including mitochondrial dysfunction, a rise in oxidative stress, activation of glial cells, and damage to the blood–brain barrier (BBB), resulting in paracellular leakage. Currently, there are no FDA-approved drugs for TBI, but existing approaches rely on delivering micro- and macromolecular treatments, which are constrained by the BBB, poor retention, off-target toxicity, and the complex pathology of TBI. Therefore, there is a demand for innovative and alternative therapeutics with effective delivery tactics for the diagnosis and treatment of TBI. Tissue engineering, which includes the use of biomaterials, is one such alternative approach. Biomaterials, such as hydrogels, including self-assembling peptides and electrospun nanofibers, can be used alone or in combination with neuronal stem cells to induce neurite outgrowth, the differentiation of human neural stem cells, and nerve gap bridging in TBI. This review examines the inclusion of biomaterials as potential treatments for TBI, including their types, synthesis, and mechanisms of action. This review also discusses the challenges faced by the use of biomaterials in TBI, including the development of biodegradable, biocompatible, and mechanically flexible biomaterials and, if combined with stem cells, the survival rate of the transplanted stem cells. A better understanding of the mechanisms and drawbacks of these novel therapeutic approaches will help to guide the design of future TBI therapies.

show abstract

“…According to the above, following the concept of ‘adaptive biomaterials carried with neurotrophic factors’ [ 60 ], in this work, we exploited the ability of the three peptide sequences—BDNF(1-12)-FAM, NT3(1-13)-FAM, and NGF(1-14)-FAM, where -FAM stands for 5(6)-carboxyfluorescein, which is the fluorescent dye used to label the peptides via covalent bonds and immobilized onto GO sheets via physisorption—to promote angiogenesis and neurogenesis. Indeed, GO also has a great potential for applications in angiogenesis, as well as cancer therapy, due to its pro- or anti-angiogenic activity and wound healing potential [ 61 ].…”

Section: Introductionmentioning

confidence: 99%

Bioinspired Nanoplatforms Based on Graphene Oxide and Neurotrophin-Mimicking Peptides

et al. 2023

View full text Add to dashboard Cite

Neurotrophins (NTs), which are crucial for the functioning of the nervous system, are also known to regulate vascularization. Graphene-based materials may drive neural growth and differentiation, and, thus, have great potential in regenerative medicine. In this work, we scrutinized the nano–biointerface between the cell membrane and hybrids made of neurotrophin-mimicking peptides and graphene oxide (GO) assemblies (pep−GO), to exploit their potential in theranostics (i.e., therapy and imaging/diagnostics) for targeting neurodegenerative diseases (ND) as well as angiogenesis. The pep−GO systems were assembled via spontaneous physisorption onto GO nanosheets of the peptide sequences BDNF(1-12), NT3(1-13), and NGF(1-14), mimicking the brain-derived neurotrophic factor (BDNF), the neurotrophin 3 (NT3), and the nerve growth factor (NGF), respectively. The interaction of pep−GO nanoplatforms at the biointerface with artificial cell membranes was scrutinized both in 3D and 2D by utilizing model phospholipids self-assembled as small unilamellar vesicles (SUVs) or planar-supported lipid bilayers (SLBs), respectively. The experimental studies were paralleled via molecular dynamics (MD) computational analyses. Proof-of-work in vitro cellular experiments with undifferentiated neuroblastoma (SH-SY5Y), neuron-like, differentiated neuroblastoma (dSH-SY5Y), and human umbilical vein endothelial cells (HUVECs) were carried out to shed light on the capability of the pep−GO nanoplatforms to stimulate the neurite outgrowth as well as tubulogenesis and cell migration.

show abstract

Recent Advances in Biomaterials‐Based Therapies for Alleviation and Regeneration of Traumatic Brain Injury

Cited by 11 publications

References 167 publications

Bibliometric analysis of stem cells for spinal cord injury: current status and emerging frontiers

Bibliometric analysis of stem cells for spinal cord injury: current status and emerging frontiers

Biomaterials in Traumatic Brain Injury: Perspectives and Challenges

Bioinspired Nanoplatforms Based on Graphene Oxide and Neurotrophin-Mimicking Peptides

Contact Info

Product

Resources

About